Oncoinvent ASA (OSL:ONCIN) EPS without NRI: kr-142.76 (TTM As of Dec. 2025)


OSL:ONCIN Oncoinvent ASA OSL:ONCIN
37 GF Score
Price kr66.00
GF Value kr973.15
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA EPS without NRI?

Oncoinvent ASA OSL:ONCIN +14.58% 37 EPS without NRI is kr-142.76 as of Dec. 2025. GuruFocus rates OSL:ONCIN with a GF Score™ of 37/100 and a GF Value™ of kr973.15 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,168 Biotechnology companies, Oncoinvent ASA ranks better than 96.06% on this metric.

Oncoinvent ASA's earnings per share without non-recurring items for the six months ended in Dec. 2025 was kr-53.69. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was kr-142.76.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 83.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 67.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Oncoinvent ASA's EPS without NRI or its related term are showing as below:

OSL:ONCIN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -35.4   Med: 2.35   Max: 83
Current: 83

During the past 11 years, Oncoinvent ASA's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 83.00% per year. The lowest was -35.40% per year. And the median was 2.35% per year.

OSL:ONCIN's 3-Year EPS without NRI Growth Rate is ranked better than
96.06% of 1168 companies
in the Biotechnology industry
Industry Median: 16.4 vs OSL:ONCIN: 83.00

Oncoinvent ASA's EPS (Diluted) for the six months ended in Dec. 2025 was kr-68.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-157.08.

Oncoinvent ASA's EPS (Basic) for the six months ended in Dec. 2025 was kr-68.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-157.08.


Oncoinvent ASA  (OSL:ONCIN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Oncoinvent ASA EPS without NRI Related Terms


Oncoinvent ASA EPS without NRI Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA EPS without NRI Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19,475.38 -21,852.43 -833.08 -561.00 -107.54

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -796.56 -174.95 -198.00 -89.08 -53.69

OSL:ONCIN vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Oncoinvent ASA's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncoinvent ASA PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Oncoinvent ASA's PE Ratio without NRI falls into.


OSL:ONCIN
37GF Score
Oncoinvent ASA OSL:ONCIN
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-142.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr-142.76 mean?
Oncoinvent ASA (OSL:ONCIN) has a EPS without NRI of kr-142.76 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Oncoinvent ASA and its competitors. According to the industry distribution chart, Oncoinvent ASA ranks #46 out of 1168 companies in the Biotechnology industry, placing it in the top 3.9%.
Is Oncoinvent ASA's EPS without NRI too high?
Oncoinvent ASA's current EPS without NRI is kr-142.76. Based on the distribution chart, Oncoinvent ASA ranks #46 out of 1168 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #46 out of 1168 companies for EPS without NRI. This places Oncoinvent ASA in the top 4% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Oncoinvent ASA and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current EPS without NRI is kr-142.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Based on GuruFocus' analysis, Oncoinvent ASA (OSL:ONCIN) is currently considered Possible Value Trap. The stock's GF Value™ is kr973.15, compared to a current price of kr66.00 — trading 93.2% below its estimated fair value. The current EPS without NRI is kr-142.76. Oncoinvent ASA's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Oncoinvent ASA (OSL:ONCIN), the current EPS without NRI is kr-142.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (OSL:ONCIN) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr66.00 is trading 93.2% below its estimated GF Value™ of kr973.15. GuruFocus considers Oncoinvent ASA to be Possible Value Trap.

Key valuation signals for OSL:ONCIN:

  • EPS without NRI: kr-142.76
  • GF Value™: kr973.15 vs. price of kr66.00 (93.2% below fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the OSL:ONCIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncoinvent ASA Business Description

Other Exchanges 0RU5:UK7BG:Germany
Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
37GF Score

Get the complete analysis for OSL:ONCIN

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr66.00
Price
kr973.15
GF Value